Sino Biopharmaceutical Presents TQB2102 Phase I Results at ASCO 2025
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary results from a Phase I clinical study...
BeiGene Rebrands to BeOne Medicines and Relocates to Switzerland
BeiGene (NASDAQ: ONC, HKG: 6160, SHA: 688235), a global oncology company, has officially rebranded to...
Betta Pharmaceuticals Partners with BioRay for Herceptin Biosimilar Anruize
China-based Betta Pharmaceuticals (SHE: 300558) announced a strategic partnership with fellow domestic firm BioRay Biopharmaceutical....
China’s NMPA Approves Lifetech’s Aortic Fenestration Stent System
China’s National Medical Products Administration (NMPA) recently approved an innovative aortic in-situ fenestration branch reconstruction...
Phanes Therapeutics Doses First Patient in CD73 Antibody Clinical Study
Sino-US biotech Phanes Therapeutics Inc. announced the first patient dosing in a clinical study for...
StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment
Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for...
Sinotau Pharma Files for HK IPO Focused on Radiopharmaceutical Pipeline
China-based Beijing Sinotau International Pharmaceutical Technology Co., Ltd., a leader in nuclear medicine (radiopharmaceuticals), announced...
Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC
Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech...
Eisai’s Dayvigo Granted NMPA Approval for Insomnia Treatment
Japan-based Eisai Co., Ltd. (TYO: 4523) announced that it has received marketing approval from China’s...
Harbin Gloria Partners with Kowa Pharmaceuticals to Promote Parmodia in China
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced last week that it has entered...
BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology company proposing to rename...
Ayshealth Technology Secures Angel Funding for Artificial Blood Vessel Research
Guangzhou-based Ayshealth Technology, a developer of tissue repair and reconstruction devices, has reportedly secured an...
Shanghai Pharma Collaborates with Novartis China on Ophthalmic Products
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) announced this week a strategic...
Kexing Pharma’s GB18 Receives NMPA Approval for Cancer Cachexia Trial
China-based Kexing Pharmaceutical (SHA: 688136) announced that it has received approval from the National Medical...
Gilead Sciences to Acquire Hookipa’s HB-400 and HB-500 Vaccine Programs
US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-4712 Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from the...
Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts
Guangzhou-based biotech Bio-Thera Solutions (SHA: 688177) announced the termination of a multi-center, randomized, double-blinded Phase...
Fosun Pharma’s HLX22 Granted Orphan Drug Designation by EU Commission
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
UCB Launches Rystiggo in China for Generalized Myasthenia Gravis
Belgium-based biopharma UCB (EBR: UCB) announced the official market launch of Rystiggo (rozanolixizumab) in China....
Bio-Thera Solutions’ BAT2206 Biosimilar of Stelara Gains FDA Approval
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced that it has received Biologic License Application (BLA)...